Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bone Biologics Corp

2.25
+0.17008.17%
Post-market: 2.21-0.0400-1.78%16:34 EDT
Volume:77.64K
Turnover:168.78K
Market Cap:4.04M
PE:-0.11
High:2.29
Open:2.13
Low:2.11
Close:2.08
52wk High:16.50
52wk Low:2.08
Shares:1.80M
Float Shares:1.45M
Volume Ratio:2.12
T/O Rate:5.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-20.8847
EPS(LYR):-28.9669
ROE:-88.80%
ROA:-52.63%
PB:0.61
PE(LYR):-0.08

Loading ...

Company Profile

Company Name:
Bone Biologics Corp
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
2
Office Location:
2 Burlington Woods Drive,Suite 100,Burlington,Massachusetts,United States
Zip Code:
01803
Fax:
- -
Introduction:
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Directors

Name
Position
Don Hankey
Chairman of the Board
Bruce Stroever
Director
Erick Lucera
Director
Sid Angle
Director

Shareholders

Name
Position
Jeffrey Frelick
Chief Executive Officer and President
Deina H. Walsh
Chief Financial Officer